Peter B. Gilbert
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · 549 works · 31,136 citations · h-index 78
Top works
- Prospects for a safe COVID-19 vaccine
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
- Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
- Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
- Barriers to Antiretroviral Adherence for Patients Living with HIV Infection and AIDS in Botswana
- Evidence for antibody as a protective correlate for COVID-19 vaccines
- Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand
- Breastfeeding Plus Infant Zidovudine Prophylaxis for 6 Months vs Formula Feeding Plus Infant Zidovudine for 1 Month to Reduce Mother-to-Child HIV Transmission in Botswana
- Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
- Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies
- Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
- A Framework for Assessing Immunological Correlates of Protection in Vaccine Trials
- Correlation between Immunologic Responses to a Recombinant Glycoprotein 120 Vaccine and Incidence of HIV‐1 Infection in a Phase 3 HIV‐1 Preventive Vaccine Trial
- Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials
- Nomenclature for Immune Correlates of Protection After Vaccination
- Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines
- Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
- Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG